TY - JOUR
T1 - Global airways
T2 - a Danish nationwide real-life registry of biologic therapy for chronic rhinosinusitis with nasal polyps
AU - Backer, Vibeke
AU - Aanæs, Kasper
AU - Larsen, Bent Ivan
AU - Haase, Christiane
AU - Homøe, Anne-Sophie
AU - Tidemandsen, Jens
AU - Ovesen, Therese
AU - Madzak, Adnan
AU - Samuelsen, Grethe
AU - Andersen, Jonas Hjelm
AU - Meyer, Lars Christian
AU - Petersen, Kristian Bruun
AU - Hermanrud, Thorbjørn
AU - Schousboe, Lars Peter
AU - Pedersen, Christian Korsgaard
AU - Hansen, Kjeld
AU - Pauli, Søren
AU - Filtenborg, Mads Vrelits
AU - Lange, Bibi
AU - Homøe, Preben
AU - von Buchwald, Christian
AU - Kjeldsen, Anette
N1 - © 2026 Backer, Aanæs, Larsen, Haase, Homøe, Tidemandsen, Ovesen, Madzak, Samuelsen, Andersen, Meyer, Petersen, Hermanrud, Schousboe, Pedersen, Hansen, Pauli, Filtenborg, Lange, Homøe, von Buchwald and Kjeldsen.
PY - 2026
Y1 - 2026
N2 - BACKGROUND: The relationship between chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) and type 2 inflammation has led to the use of biologic treatment for uncontrolled cases. As biologic treatment remains a relatively new approach for CRSwNP, systematic assessment and collection of high-quality, real-world data are crucial. This study established the national Global Airways registry to collect longitudinal data over a period of 12 months for patients with CRSwNP treated with biological therapies according to criteria established by the Danish Health Authority.METHODS: All participating sites conducted systematic assessments of patients with CRSwNP referred for initiation of biologic treatment. Clinical and patient-reported outcome data were collected at baseline and after 6 and 12 months of treatment and were entered in real-time into the Global Airways registry. Comparisons were performed between patients eligible or not eligible for biologic therapy and between pre- and post-treatment timepoints.RESULTS: A total of 513 patients were enrolled between November 2022 and December 2024, with 310 receiving treatments with biologics (mepolizumab or dupilumab). Mean [standard deviation (SD)] age in the treatment group was 49.7 (14) years and 66% were male. The median number of previous endoscopic sinus surgeries was 2 (range 1-16). Baseline mean (SD) scores were as follows: Nasal Polyp Score (NPS) 4.8 (1.7); Sinonasal Outcome Test (SNOT)-22 68.7 (18.7); Visual Analog Scale (VAS) CRS 84.1 (16); and Sniffin' Sticks-16 (SST-16) score 4.8 (3). Asthma was present in 204 (66%) patients, with a mean (SD) Asthma Control Questionnaire (ACQ)-5 score of 2.1 (1.5). Among patients with available data at both 6 and 12 months (n = 160), mean SNOT-22 scores improved from 68 to 29 and 24, NPS from 5.1 to 3.0 and 2.4, SST-16 from 4.7 to 9.2 and 10.0, and ACQ-5 from 2.3 to 1.0 and 0.8 (all p < 0.001).CONCLUSIONS: The Global Airways registry was an effective working tool that ensured collection of important real-world data when moving from surgery to biologics. Furthermore, the registry demonstrated the sustained effectiveness of biologic therapy in patients with refractory CRSwNP and provided a robust foundation for defining CRS phenotypes and advancing targeted treatment strategies.
AB - BACKGROUND: The relationship between chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) and type 2 inflammation has led to the use of biologic treatment for uncontrolled cases. As biologic treatment remains a relatively new approach for CRSwNP, systematic assessment and collection of high-quality, real-world data are crucial. This study established the national Global Airways registry to collect longitudinal data over a period of 12 months for patients with CRSwNP treated with biological therapies according to criteria established by the Danish Health Authority.METHODS: All participating sites conducted systematic assessments of patients with CRSwNP referred for initiation of biologic treatment. Clinical and patient-reported outcome data were collected at baseline and after 6 and 12 months of treatment and were entered in real-time into the Global Airways registry. Comparisons were performed between patients eligible or not eligible for biologic therapy and between pre- and post-treatment timepoints.RESULTS: A total of 513 patients were enrolled between November 2022 and December 2024, with 310 receiving treatments with biologics (mepolizumab or dupilumab). Mean [standard deviation (SD)] age in the treatment group was 49.7 (14) years and 66% were male. The median number of previous endoscopic sinus surgeries was 2 (range 1-16). Baseline mean (SD) scores were as follows: Nasal Polyp Score (NPS) 4.8 (1.7); Sinonasal Outcome Test (SNOT)-22 68.7 (18.7); Visual Analog Scale (VAS) CRS 84.1 (16); and Sniffin' Sticks-16 (SST-16) score 4.8 (3). Asthma was present in 204 (66%) patients, with a mean (SD) Asthma Control Questionnaire (ACQ)-5 score of 2.1 (1.5). Among patients with available data at both 6 and 12 months (n = 160), mean SNOT-22 scores improved from 68 to 29 and 24, NPS from 5.1 to 3.0 and 2.4, SST-16 from 4.7 to 9.2 and 10.0, and ACQ-5 from 2.3 to 1.0 and 0.8 (all p < 0.001).CONCLUSIONS: The Global Airways registry was an effective working tool that ensured collection of important real-world data when moving from surgery to biologics. Furthermore, the registry demonstrated the sustained effectiveness of biologic therapy in patients with refractory CRSwNP and provided a robust foundation for defining CRS phenotypes and advancing targeted treatment strategies.
KW - asthma
KW - chronic rhinosinusitis with nasal polyps
KW - monoclonal antibodies
KW - real-life data
KW - registry
KW - type 2 inflammation
UR - https://www.scopus.com/pages/publications/105028481327
U2 - 10.3389/falgy.2025.1735943
DO - 10.3389/falgy.2025.1735943
M3 - Journal article
C2 - 41608597
SN - 2673-6101
VL - 6
JO - Frontiers in allergy
JF - Frontiers in allergy
M1 - 1735943
ER -